about
Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Preclinical validation of interleukin 6 as a therapeutic target in multiple myelomaALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma.Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.Nek2 is a novel regulator of B cell development and immunological response.Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.Role of NEK2A in human cancer and its therapeutic potentials.CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myelomaEarly versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trialsInhibition of Nek2 by small molecules affects proteasome activity.Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalitiesMyeloma cell-derived Runx2 promotes myeloma progression in bone.Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.Peptide Decoration of Nanovehicles to Achieve Active Targeting and Pathology-Responsive Cellular Uptake for Bone Metastasis Chemotherapy.Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma CellsCarfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapyFOXM1 is a therapeutic target for high-risk multiple myeloma.Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myelomaDecreased ferroportin promotes myeloma cell growth and osteoclast differentiationMechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs.Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.Antitumor activity of fucoidan against diffuse large B cell lymphoma in vitro and in vivo.Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism.VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.Adoptive B-cell transfer mouse model of human myelomaDrug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics.Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells.Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid.High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.A common region of allelic loss on chromosome region 3p25.3-26.3 in nasopharyngeal carcinomaImmunization with a recombinant MAGE-A3 protein after high-dose therapy for myelomaPrognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantationsPrognostic value of high serum lactate dehydrogenase in plasma cell dyscrasias: a re-evaluation in the context of cytogenetic aberration data
P50
Q26785497-3D8AEE28-3FD9-4FC3-9E90-68578ACFC011Q27027729-808AEEA7-6F1E-4388-8ED7-7769FB8FE29AQ33599165-30B9A8E4-1951-40A1-BC5B-F99898E36C64Q33901870-3BABE346-792A-42A2-BE95-4DC81CEF4CB4Q34609883-D4B990C4-E24A-47F7-8020-9B9EF48BB07DQ35024457-F2CE32C7-E462-4485-9272-6723900A109BQ35090475-93D8E599-1E71-4B13-9C3B-FF209C6C8A5AQ35247381-9FB12358-430F-4A93-A946-8D89CD3759BEQ35298727-8D47DDC6-5184-4DCA-8122-0B5E5FF0905EQ35329864-4E631685-0DA8-40D6-88B0-E9390A03C820Q35534247-2D8C67C1-BF8F-4960-BC18-3BB802169ACAQ35692401-10F54F42-2792-41C3-BFA9-13B260034133Q35720912-69CCB7EA-17B2-4D9E-A3EE-D6E563FD83D1Q35737342-7CE52FA6-CC4D-4EF4-81EC-8EA978135489Q36208283-48AFAED6-4042-42B0-9AD0-32484CB2AE15Q36413676-5334DC0C-9348-4138-98FD-EFDBC04ED0F7Q36616750-4063B0D6-7FE2-4B2D-884C-79287F51EF91Q36783627-E312867B-D316-48BE-94D7-924CA342250BQ36980287-F4E0F9A6-3771-4954-910E-0E3706953F71Q37097239-DFE219BC-6B37-4885-B96B-382428F2FC36Q38056080-82BBA6DB-01D6-4460-97DB-B63355F86E61Q38315523-A73E66F3-F935-4242-91EC-54D3855A72ECQ38342111-7676A055-6B46-4B34-973D-3186512F8B77Q38836263-F1B75304-105B-424B-951E-DB07615C8E56Q38992850-F3A6440A-0023-43BF-B592-B08FA2082CAAQ39103567-37F2C956-C4EB-43DC-8F05-365A937C2CF8Q39893133-690192C6-488D-40D3-A5B3-81DE3605DEF8Q40526451-B80938CE-CD4D-4DEB-949C-0761E71BAD98Q40797432-92BFE932-81E7-4577-833C-8ACAE18F8B4FQ41000131-C1FABAF7-490B-4971-BBBC-37FF05AE0F6EQ41470476-2090A5A7-38EE-4315-9E33-74CF0211E0A3Q42009130-83BC0F6F-E0E4-4279-ABA4-DBD6246A3E8AQ42953783-2CD43848-C5B8-4A05-B413-179F0F9BE5EBQ43245396-D742A812-1D72-49B2-BE9A-F93FA8EEA2F9Q46897494-DE543891-27DD-401C-A327-A5FB759C849DQ49777578-D87BF433-39BC-4E99-A754-E2B3B6C0B37BQ77132622-A56AD949-A839-454C-8BAB-C5744985D542Q80121138-FF4468B2-117E-44AC-8A15-A044548A8952Q83318096-DC76E960-8969-4B48-82A4-062E68C91A6BQ86150579-AF168E3C-A3EF-496D-AD9C-3010917212E6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fenghuang Zhan
@ast
Fenghuang Zhan
@en
Fenghuang Zhan
@es
Fenghuang Zhan
@nl
type
label
Fenghuang Zhan
@ast
Fenghuang Zhan
@en
Fenghuang Zhan
@es
Fenghuang Zhan
@nl
prefLabel
Fenghuang Zhan
@ast
Fenghuang Zhan
@en
Fenghuang Zhan
@es
Fenghuang Zhan
@nl
P106
P1153
7005027931
P31
P496
0000-0001-6208-1676